Several analysts have recently updated their ratings and price targets for Advanced Accelerator Applications (NASDAQ: AAAP):

  • 8/3/2017 – Advanced Accelerator Applications was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/1/2017 – Advanced Accelerator Applications was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “
  • 7/27/2017 – Advanced Accelerator Applications was upgraded by analysts at JMP Securities from a “market perform” rating to an “outperform” rating. They now have a $69.00 price target on the stock.
  • 7/27/2017 – Advanced Accelerator Applications was given a new $47.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/14/2017 – Advanced Accelerator Applications was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/11/2017 – Advanced Accelerator Applications was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $44.00 price target on the stock. According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “
  • 6/23/2017 – Advanced Accelerator Applications was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/23/2017 – Advanced Accelerator Applications had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $50.00 price target on the stock.
  • 6/15/2017 – Advanced Accelerator Applications is now covered by analysts at J P Morgan Chase & Co. They set an “overweight” rating and a $50.00 price target on the stock.
  • 6/14/2017 – Advanced Accelerator Applications was downgraded by analysts at TheStreet from a “c-” rating to a “d” rating.

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) traded up 1.00% during trading on Monday, hitting $49.61. The company had a trading volume of 81,814 shares. Advanced Accelerator Applications S.A. has a 12-month low of $23.50 and a 12-month high of $51.02. The firm’s market cap is $2.19 billion.

Advanced Accelerator Applications SA is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.

Receive News & Ratings for Advanced Accelerator Applications SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications SA and related companies with MarketBeat.com's FREE daily email newsletter.